Last reviewed · How we verify
Genetically modified CTLs
At a glance
| Generic name | Genetically modified CTLs |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies (PHASE1)
- LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) (PHASE1)
- Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Genetically modified CTLs CI brief — competitive landscape report
- Genetically modified CTLs updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI